Resveratrol modulates the Nrf2/NF-κB pathway and inhibits TSLP-mediated atopic march

Main Article Content

Quan He
Weihua Liu
Zi Chen
Guangfei Wei
Jingxian Jiang
Liuchao Zhang
Linfu Zhou

Keywords

atopic march, NF-ΚB, Nrf2, resveratrol, TSLP

Abstract

Background: Resveratrol has been found to have anti-inflammatory and anti-allergic properties. The effects of resveratrol on thymic stromal lymphopoietin (TSLP)-mediated atopic march remain unclear.


Purpose: To explore the potential role of resveratrol in TSLP-mediated atopic march.


Methods: The atopic march mouse model was established by topical application of MC903 (a vitamin D3 analog). Following the treatment with resveratrol, airway resistance in mice was discovered by pulmonary function apparatus, and the number of total cells, neutrophils, and eosinophils in bronchoalveolar lavage fluid was counted. The histopathological features of pulmonary and ear skin tissues, inflammation, and cell infiltration were determined by hematoxylin and eosin staining. The messenger RNA (mRNA) levels of TSLP, immunoglobulin E, interleukin (IL)-4, IL-5, and IL-13 were measured by real-time quantitative polymerase chain reaction. The protein expression of nuclear factor kappa B (NF-κB)/nuclear factor erythroid 2-related factor 2 (Nrf2) signaling-associated molecules (p-p65, p65, p-I kappa B kinase alpha (IκBα), IκBα, Nrf2, and TSLP) in lung and ear skin tissues were assessed by Western blot analysis.


Results: Resveratrol attenuated airway resistance and infiltration of total cells, eosinophils, and neutrophils in both lung and ear skin tissues. Resveratrol ameliorates serum inflammatory markers in allergic mice. Moreover, the phosphorylation levels of NF-κB pathway-related proteins were significantly reduced by administration of resveratrol in allergic lung and ear skin tissues. Similarly, the protein expression of TSLP in both lung and ear skin tissues was reduced by resveratrol, and Nrf2, a protector molecule, was increased with resveratrol treatment.


Conclusion: Resveratrol attenuates TSLP-reduced atopic march through ameliorating inflammation and cell infiltration in pulmonary and ear skin tissues by inhibiting the abnormal activation of NF-κB signaling pathway.

Abstract 501 | PDF Downloads 628 HTML Downloads 0 XML Downloads 34

References

1. Bantz SK, Zhu Z, Zheng T. The atopic march: Progression from atopic dermatitis to allergic rhinitis and asthma. J Clin Cell Immunol. 2014;5(2):202. 10.4172/2155-9899.1000202

2. Caglayan Sozmen S, Karaman M, Cilaker Micili S, Isik S, Arikan Ayyildiz Z, Bagriyanik A, et al. Resveratrol ameliorates 2,4-dinitrofluorobenzene-induced atopic dermatitis-like lesions through effects on the epithelium. PeerJ. 2016;4:e1889. 10.7717/peerj.1889

3. Alharris E, Alghetaa H, Seth R, Chatterjee S, Singh NP, Nagarkatti M, et al. Resveratrol attenuates allergic asthma and associated inflammation in the lungs through regulation of miRNA-34a that targets FoxP3 in mice. Front Immunol. 2018;9:2992. 10.3389/fimmu.2018.02992

4. Zhang YF, Liu QM, Gao YY, Liu B, Liu H, Cao MJ, et al. Attenuation of allergic responses following treatment with resveratrol in anaphylactic models and IgE-mediated mast cells. Food Funct. 2019;10(4):2030–9. 10.1039/C9FO00077A

5. Alharris E, Mohammed A, Alghetaa H, Zhou J, Nagarkatti M, Nagarkatti P. The ability of resveratrol to attenuate ovalbumin-mediated allergic asthma is associated with changes in microbiota involving the gut-lung axis, enhanced barrier function and decreased inflammation in the lungs. Front Immunol. 2022;13:805770. 10.3389/fimmu.2022.805770

6. Zhang W, Tang R, Ba G, Li M, Lin H. Anti-allergic and anti-inflammatory effects of resveratrol via inhibiting TXNIP-oxidative stress pathway in a mouse model of allergic rhinitis. World Allergy Organ J. 2020;13(10):100473. 10.1016/j.waojou.2020.100473

7. Wang S, Gong L, Mo Y, Zhang J, Jiang Z, Tian Z, et al. Resveratrol attenuates inflammation and apoptosis through alleviating endoplasmic reticulum stress via Akt/mTOR pathway in fungus-induced allergic airways inflammation. Int Immunopharmacol. 2022;103:108489. 10.1016/j.intimp.2021.108489

8. Shang X, Lin K, Yu R, Zhu P, Zhang Y, Wang L, et al. Resveratrol protects the myocardium in sepsis by activating the phosphatidylinositol 3-kinases (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway and inhibiting the nuclear factor-kappaB (NF-kappaB) signaling pathway. Med Sci Monit. 2019;25:9290–8. 10.12659/MSM.918369

9. Kim EN, Lim JH, Kim MY, Ban TH, Jang IA, Yoon HE, et al. Resveratrol, an Nrf2 activator, ameliorates aging-related progressive renal injury. Aging (Albany NY). 2018;10(1):83–99. 10.18632/aging.101361

10. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001;29(9):e45. 10.1093/nar/29.9.e45

11. van der Weegen Y, Golan-Berman H, Mevissen TET, Apelt K, González-Prieto R, Goedhart J, et al. The cooperative action of CSB, CSA, and UVSSA target TFIIH to DNA damage-stalled RNA polymerase II. Nat Commun. 2020;11(1):2104. 10.1038/s41467-020-19643-7

12. Royce SG, Dang W, Yuan G, Tran J, El Osta A, Karagiannis TC, et al. Resveratrol has protective effects against airway remodeling and airway hyperreactivity in a murine model of allergic airways disease. Pathobiol Aging Age Relat Dis. 2011;1. 10.3402/PBA.v1i0.7134

13. Civelek M, Bilotta S, Lorentz A. Resveratrol attenuates mast cell mediated allergic reactions: Potential for use as a nutraceutical in allergic diseases? Mol Nutr Food Res. 2022; 66(15):e2200170. 10.1002/mnfr.202200170

14. Yang CC, Hung YL, Ko WC, Tsai YJ, Chang JF, Liang CW, et al. Effect of neferine on DNCB-induced atopic dermatitis in HaCaT cells and BALB/c mice. Int J Mol Sci. 2021;22(15):8237. 10.3390/ijms22158237

15. Liu J, Xu Y, Yan M, Yu Y, Guo Y. 18beta-Glycyrrhetinic acid suppresses allergic airway inflammation through NF-kappaB and Nrf2/HO-1 signaling pathways in asthma mice. Sci Rep. 2022;12(1):3121. 10.1038/s41598-022-06455-6

16. Wen W, Zhu S, Ma R, Wang L, Shen X, Li Y, et al. Correlation analysis of TGF-β1, TIMP-1, IL-1, IL-4, IL-6, IL-17, and TNF-α in refractory chronic rhinosinusitis: A retrospective study. Allergol Immunopathol (Madr). 2022;50(4):137-142. 10.15586/aei.v50i4.527

17. Batrakova E, Kartashova O, Babaskina L, Pashanova O. Effect of combined glucocorticoid therapy on bronchial asthma dynamics. Allergol Immunopathol (Madr). 2022;50(1):68–74. 10.15586/aei.v50i1.481

18. Yuan J-Y, Tong Z-Y, Dong Y-C, Zhao J-Y, Shang Y. Research progress on icariin, a traditional Chinese medicine extract, in the treatment of asthma. Allergol Immunopathol (Madr). 2022;50(1):9–16. 10.15586/aei.v50i1.490

19. Sussan TE, Gajghate S, Chatterjee S, Mandke P, McCormick S, Sudini K, et al. Nrf2 reduces allergic asthma in mice through enhanced airway epithelial cytoprotective function. Am J Physiol Lung Cell Mol Physiol. 2015;309(1):L27–36. 10.1152/ajplung.00398.2014

20. Lee JH, Lim JY, Jo EH, Noh HM, Park S, Park MC, et al. Chijabyukpi-tang inhibits pro-inflammatory cytokines and chemokines via the Nrf2/HO-1 signaling pathway in TNF-alpha/IFN-gamma-stimulated HaCaT cells and ameliorates 2,4-Dinitrochlorobenzene-induced atopic dermatitis-like skin lesions in mice. Front Pharmacol. 2020;11:1018. 10.3389/fphar.2020.01018